IN2014DN09417A - - Google Patents
Info
- Publication number
- IN2014DN09417A IN2014DN09417A IN9417DEN2014A IN2014DN09417A IN 2014DN09417 A IN2014DN09417 A IN 2014DN09417A IN 9417DEN2014 A IN9417DEN2014 A IN 9417DEN2014A IN 2014DN09417 A IN2014DN09417 A IN 2014DN09417A
- Authority
- IN
- India
- Prior art keywords
- present
- specific antibodies
- antibodies
- specificity
- affinity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
The present invention is relevant to the generation of multi- specific antibodies, antibodies that are distinguished by their ability to bind to multiple antigens with specificity and with affinity. In particular, the present invention is related to bi -specific antibodies.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261645302P | 2012-05-10 | 2012-05-10 | |
PCT/US2013/040575 WO2013170168A1 (en) | 2012-05-10 | 2013-05-10 | Multi-specific monoclonal antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN09417A true IN2014DN09417A (en) | 2015-07-17 |
Family
ID=49551307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN9417DEN2014 IN2014DN09417A (en) | 2012-05-10 | 2013-05-10 |
Country Status (13)
Country | Link |
---|---|
US (3) | US9969813B2 (en) |
EP (2) | EP3553089A1 (en) |
JP (3) | JP6267689B2 (en) |
KR (3) | KR102023401B1 (en) |
CN (2) | CN104583239B (en) |
AU (3) | AU2013259276B2 (en) |
CA (3) | CA3051210A1 (en) |
DK (1) | DK2847231T3 (en) |
ES (1) | ES2749200T3 (en) |
HK (1) | HK1210620A1 (en) |
IN (1) | IN2014DN09417A (en) |
MX (2) | MX362705B (en) |
WO (1) | WO2013170168A1 (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9969813B2 (en) | 2012-05-10 | 2018-05-15 | Bioatla, Llc | Multi-specific monoclonal antibodies |
TWI805996B (en) | 2013-08-05 | 2023-06-21 | 美商扭轉生物科技有限公司 | De novo synthesized gene libraries |
MX2016014824A (en) | 2014-05-13 | 2017-03-23 | Bioatla Llc | Conditionally active biological proteins. |
CN107074975A (en) | 2014-08-28 | 2017-08-18 | 生物蛋白有限公司 | Condition active chimeric antigen receptor for the T cell of modification |
US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
CA2975852A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
US10844373B2 (en) * | 2015-09-18 | 2020-11-24 | Twist Bioscience Corporation | Oligonucleic acid variant libraries and synthesis thereof |
KR20180058772A (en) | 2015-09-22 | 2018-06-01 | 트위스트 바이오사이언스 코포레이션 | Flexible substrate for nucleic acid synthesis |
US10697972B2 (en) | 2016-01-12 | 2020-06-30 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
AU2017207263B2 (en) | 2016-01-12 | 2021-01-07 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
AU2017238172A1 (en) | 2016-03-21 | 2018-09-13 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
IL262404B2 (en) | 2016-05-13 | 2024-04-01 | Bioatla Llc | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
US10417457B2 (en) | 2016-09-21 | 2019-09-17 | Twist Bioscience Corporation | Nucleic acid based data storage |
WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
EP3586255A4 (en) | 2017-02-22 | 2021-03-31 | Twist Bioscience Corporation | Nucleic acid based data storage |
EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
SG11201912057RA (en) | 2017-06-12 | 2020-01-30 | Twist Bioscience Corp | Methods for seamless nucleic acid assembly |
US20210206882A1 (en) * | 2017-08-01 | 2021-07-08 | Ab Studio Inc. | Bispecific antibodies and uses thereof |
CN111566125A (en) | 2017-09-11 | 2020-08-21 | 特韦斯特生物科学公司 | GPCR binding proteins and synthesis thereof |
US10894242B2 (en) | 2017-10-20 | 2021-01-19 | Twist Bioscience Corporation | Heated nanowells for polynucleotide synthesis |
EP3765516A2 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
US20210238280A1 (en) | 2018-03-14 | 2021-08-05 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2019222706A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
CA3103414A1 (en) * | 2018-06-14 | 2019-12-19 | Bioatla, Inc. | Multi-specific antibody constructs |
DE202019005887U1 (en) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
KR20210041604A (en) * | 2018-08-21 | 2021-04-15 | 바이오아트라, 인코퍼레이티드 | Conditionally active protein showing pH selectivity |
EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
JP2022521937A (en) | 2019-02-21 | 2022-04-13 | マレンゴ・セラピューティクス,インコーポレーテッド | Antibody molecules that bind to NKp30 and their use |
JP2022521750A (en) | 2019-02-21 | 2022-04-12 | マレンゴ・セラピューティクス,インコーポレーテッド | Multifunctional molecule that binds to calreticulin and its use |
CN114126714A (en) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | anti-TCR antibody molecules and uses thereof |
CA3130628A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
CN114026122A (en) | 2019-02-21 | 2022-02-08 | 马伦戈治疗公司 | Multifunctional molecules that bind to T cell-associated cancer cells and uses thereof |
CN113785057A (en) | 2019-02-26 | 2021-12-10 | 特韦斯特生物科学公司 | Variant nucleic acid libraries for antibody optimization |
JP2022524081A (en) | 2019-03-08 | 2022-04-27 | オブシディアン セラピューティクス, インコーポレイテッド | Human Carbonic Amhydrase 2 Compositions and Methods for Adjustable Control |
EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
US11332738B2 (en) | 2019-06-21 | 2022-05-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
WO2021084104A1 (en) | 2019-10-30 | 2021-05-06 | Bioinvent International Ab | Tetravalent antibody molecules |
EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics Inc | Multifunctional molecules that bind to cd33 and uses thereof |
EP4139363A1 (en) | 2020-04-24 | 2023-03-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
KR20230074144A (en) | 2020-08-26 | 2023-05-26 | 마렝고 테라퓨틱스, 인크. | Antibody molecules that bind to NKp30 and uses thereof |
EP4204458A1 (en) | 2020-08-26 | 2023-07-05 | Marengo Therapeutics, Inc. | Methods of detecting trbc1 or trbc2 |
EP4225786A2 (en) * | 2020-10-07 | 2023-08-16 | Amgen Inc. | Rational selection of building blocks for the assembly of multispecific antibodies |
WO2022216993A2 (en) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
WO2023023055A1 (en) | 2021-08-16 | 2023-02-23 | Renagade Therapeutics Management Inc. | Compositions and methods for optimizing tropism of delivery systems for rna |
TW202325263A (en) | 2021-09-14 | 2023-07-01 | 美商雷納嘉德醫療管理公司 | Acyclic lipids and methods of use thereof |
CA3232386A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
EP0575545B1 (en) | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
JPH07503132A (en) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | Transgenic non-human animals capable of producing xenoantibodies |
AU690088B2 (en) | 1992-11-24 | 1998-04-23 | G.D. Searle & Co. | Interleukin-3 (IL-3) multiple mutation polypeptides |
GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
JPH09503759A (en) | 1993-09-22 | 1997-04-15 | メディカル リサーチ カウンシル | Antibody retargeting |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
CA2253904A1 (en) | 1996-05-03 | 1997-11-13 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer |
US7011812B1 (en) | 1996-05-03 | 2006-03-14 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
CA2288600C (en) * | 1997-05-02 | 2010-06-01 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
DE69938923D1 (en) | 1998-03-27 | 2008-07-31 | Genentech Inc | SYNERGY BETWEEN APO-2 LIGAND AND ANTIBODY AGAINST HER-2 |
US7833528B2 (en) | 1998-06-22 | 2010-11-16 | Immunomedics, Inc. | Use of multispecific, non-covalent complexes for targeted delivery of therapeutics |
WO2001097855A2 (en) | 2000-06-20 | 2001-12-27 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
US8034903B2 (en) | 2000-10-20 | 2011-10-11 | Chugai Seiyaku Kabushiki Kaisha | Degraded TPO agonist antibody |
US20020168343A1 (en) | 2001-02-14 | 2002-11-14 | Curiel David T. | Combined transductional and transcriptional targeting system for improved gene delivery |
MXPA03007323A (en) | 2001-02-19 | 2003-12-12 | Merck Patent Gmbh | Artificial proteins with reduced immunogenicity. |
US20050142539A1 (en) * | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
DE60327199D1 (en) | 2002-04-26 | 2009-05-28 | Chugai Pharmaceutical Co Ltd | PROCESS FOR SCREENING AGONISTIC ANTIBODIES |
CN100480260C (en) * | 2002-07-18 | 2009-04-22 | 克鲁塞尔荷兰公司 | Recombinant production of mixtures of antibodies |
AU2013200009B2 (en) * | 2002-07-18 | 2015-05-07 | Merus N.V. | Recombinant production of mixtures of antibodies |
EP1605058B1 (en) * | 2003-01-21 | 2009-05-13 | Chugai Seiyaku Kabushiki Kaisha | Method of screening light chain of antibody light chains |
JP4794301B2 (en) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | Antibody production method |
US20090191213A9 (en) | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
WO2005030793A2 (en) * | 2003-09-24 | 2005-04-07 | Millennium Pharmaceuticals, Inc. | Antibodies which bind human cxcr3 |
GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
JP2008523083A (en) | 2004-12-08 | 2008-07-03 | イムノメディクス, インコーポレイテッド | Methods and compositions for immunotherapy and detection of inflammatory and immune dysregulated diseases, infectious diseases, pathological angiogenesis and cancer |
WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
JP4937138B2 (en) | 2005-01-05 | 2012-05-23 | エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Synthetic immunoglobulin domains with binding properties designed in a region of the molecule that is different from the complementarity-determining region |
AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
EP2230256A1 (en) | 2005-09-23 | 2010-09-22 | Walter Reed Army Institute of Research (WRAIR) | Antibodies with simultaneous subsite specificities to protein and lipid epitopes |
PL1989231T3 (en) | 2006-03-21 | 2015-10-30 | Genentech Inc | Combinatorial therapy involving alpha5beta1 antagonists |
WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
CA2689941C (en) * | 2007-06-25 | 2019-10-29 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
EP2069401A4 (en) | 2007-07-31 | 2011-02-23 | Medimmune Llc | Multispecific epitope binding proteins and uses thereof |
CN101842116A (en) * | 2007-08-28 | 2010-09-22 | 比奥根艾迪克Ma公司 | Compositions that bind multiple epitopes of IGF-1R |
AU2008304452B2 (en) | 2007-09-26 | 2014-01-16 | Genentech, Inc. | Novel antibodies |
EP2113255A1 (en) * | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
RU2567100C2 (en) | 2008-06-25 | 2015-10-27 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα |
EP2310508A1 (en) | 2008-07-02 | 2011-04-20 | Emergent Product Development Seattle, LLC | Tgf-b antagonist multi-target binding proteins |
NZ590668A (en) | 2008-07-02 | 2012-12-21 | Emergent Product Dev Seattle | TNF-alpha ANTAGONIST MULTI-TARGET BINDING PROTEINS |
BRPI0913991A2 (en) | 2008-07-02 | 2015-11-17 | Emergent Product Dev Seattle | il6 immunotherapy |
CA2729899A1 (en) | 2008-07-14 | 2010-01-21 | Fred J. Stevens | Methods for systematic control of protein stability |
CA2732574A1 (en) | 2008-07-28 | 2010-02-04 | Philip Tan | Multi-specific binding proteins targeting b cell disorders |
WO2010040105A2 (en) | 2008-10-02 | 2010-04-08 | Trubion Pharmaceuticals, Inc. | Cd86 antagonist multi-target binding proteins |
TWI461211B (en) | 2009-03-20 | 2014-11-21 | Genentech Inc | Anti-her antibodies |
EP2414391B1 (en) | 2009-04-02 | 2018-11-28 | Roche Glycart AG | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
DK2483310T3 (en) | 2009-09-29 | 2014-09-01 | Roche Glycart Ag | BISPECIFIC DEATH RECEPTOR AGONISTIC ANTIBODIES |
CA2778690A1 (en) | 2009-10-30 | 2011-11-05 | Bayer Healthcare Llc | Antibody mimetic scaffolds |
KR20120123299A (en) | 2009-12-04 | 2012-11-08 | 제넨테크, 인크. | Multispecific antibodies, antibody analogs, compositions, and methods |
EP2519544A1 (en) | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptide heterodimers and uses thereof |
ES2603559T5 (en) * | 2010-02-08 | 2021-02-22 | Regeneron Pharma | Mouse common light chain |
WO2011109726A2 (en) * | 2010-03-05 | 2011-09-09 | Bioatla Llc | Homologous multi-specific antibodies |
MX346731B (en) * | 2010-04-23 | 2017-03-30 | Genentech Inc * | Production of heteromultimeric proteins. |
SG10201902596TA (en) | 2010-07-16 | 2019-04-29 | Bioatla Llc | Novel methods of protein evolution |
JP5997154B2 (en) * | 2010-08-16 | 2016-09-28 | ノビミューン エスアー | Method for producing multispecific multivalent antibody |
MX355060B (en) | 2010-11-17 | 2018-04-03 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii. |
CN103384682B (en) | 2011-01-14 | 2017-04-12 | Ucb医药有限公司 | Antibody molecules which bind IL-17A and IL-17F |
EP2500073A1 (en) | 2011-03-17 | 2012-09-19 | ChromaCon AG | Method for identification and purification of multi-specific polypeptides |
CN103842383B (en) | 2011-05-16 | 2017-11-03 | 健能隆医药技术(上海)有限公司 | Polyspecific FAB fusion proteins and its application method |
WO2013003652A1 (en) | 2011-06-28 | 2013-01-03 | Sea Lane Biotechnologies, Llc | Multispecific stacked variable domain binding proteins |
UA117901C2 (en) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Antibody variants and uses thereof |
EP2543680A1 (en) | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
CN103974977A (en) | 2011-09-26 | 2014-08-06 | Jn生物科学有限责任公司 | Hybrid constant regions |
CN104302664B (en) | 2012-03-14 | 2021-11-26 | 瑞泽恩制药公司 | Multispecific antigen binding molecules and uses thereof |
WO2013142255A2 (en) | 2012-03-22 | 2013-09-26 | University Of Miami | Multi-specific binding agents |
US9969813B2 (en) * | 2012-05-10 | 2018-05-15 | Bioatla, Llc | Multi-specific monoclonal antibodies |
EP2855531A1 (en) | 2012-05-24 | 2015-04-08 | F. Hoffmann-La Roche AG | Multispecific antibodies |
CN104684928A (en) | 2012-08-02 | 2015-06-03 | Jn生物科学有限责任公司 | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
KR20140036905A (en) | 2012-09-18 | 2014-03-26 | 삼성전자주식회사 | Protein complex comprising bi-specific antibody |
GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
-
2013
- 2013-05-10 US US14/399,617 patent/US9969813B2/en active Active
- 2013-05-10 CA CA3051210A patent/CA3051210A1/en active Pending
- 2013-05-10 MX MX2014013590A patent/MX362705B/en active IP Right Grant
- 2013-05-10 KR KR1020197004783A patent/KR102023401B1/en active IP Right Grant
- 2013-05-10 CN CN201380035170.7A patent/CN104583239B/en active Active
- 2013-05-10 KR KR1020147033427A patent/KR101951641B1/en active IP Right Grant
- 2013-05-10 MX MX2019001355A patent/MX2019001355A/en unknown
- 2013-05-10 CN CN201810258801.6A patent/CN108690132B/en active Active
- 2013-05-10 ES ES13788439T patent/ES2749200T3/en active Active
- 2013-05-10 CA CA3202536A patent/CA3202536A1/en active Pending
- 2013-05-10 AU AU2013259276A patent/AU2013259276B2/en active Active
- 2013-05-10 CA CA2872908A patent/CA2872908C/en active Active
- 2013-05-10 WO PCT/US2013/040575 patent/WO2013170168A1/en active Application Filing
- 2013-05-10 IN IN9417DEN2014 patent/IN2014DN09417A/en unknown
- 2013-05-10 DK DK13788439.1T patent/DK2847231T3/en active
- 2013-05-10 EP EP19174963.9A patent/EP3553089A1/en active Pending
- 2013-05-10 KR KR1020197017228A patent/KR102089526B1/en active IP Right Grant
- 2013-05-10 JP JP2015511761A patent/JP6267689B2/en active Active
- 2013-05-10 EP EP13788439.1A patent/EP2847231B1/en active Active
-
2015
- 2015-08-26 HK HK15108289.6A patent/HK1210620A1/en unknown
-
2017
- 2017-12-22 JP JP2017246602A patent/JP6465953B2/en active Active
-
2018
- 2018-02-16 AU AU2018201159A patent/AU2018201159B2/en active Active
- 2018-03-23 US US15/934,596 patent/US20180237543A1/en not_active Abandoned
-
2019
- 2019-01-07 JP JP2019000631A patent/JP6723392B2/en active Active
- 2019-01-31 US US16/264,028 patent/US10696750B2/en active Active
-
2020
- 2020-03-25 AU AU2020202133A patent/AU2020202133B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN09417A (en) | ||
PH12017500915A1 (en) | Cd47 antibodies, methods, and uses | |
PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
MX360368B (en) | Modified antibody regions and uses thereof. | |
PH12015502565B1 (en) | Anti-transferrin receptor antibodies and methods of use | |
PH12014501758A1 (en) | Cd47 antibodies and methods of use thereof | |
MX364329B (en) | Pyrrolobenzodiazepine-antibody conjugates. | |
WO2013064701A3 (en) | Specific antibodies and their isolation with anti-idiotypic antibodies | |
EA201491947A1 (en) | ANTIBODIES AND IMMUNOCONJUGATES TO LY6E AND METHODS OF APPLICATION | |
NZ703423A (en) | Antibodies to tau | |
EA201492101A1 (en) | ANTIBODIES AGAINST FCRN | |
TN2013000292A1 (en) | Antibody molecules which bind il-17a and il-17f | |
EA201590993A1 (en) | HETERODIMERNY IMMUNOHLOBULINS | |
MX2015004421A (en) | Pyrrolobenzodiazepine-antibody conjugates. | |
SG10201703798YA (en) | Antibodies with modified affinity to fcrn that promote antigen clearance | |
MX347454B (en) | Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses. | |
WO2013021279A3 (en) | Highly galactosylated antibodies | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
WO2011109726A3 (en) | Homologous multi-specific antibodies | |
IN2015DN00634A (en) | ||
MX350335B (en) | Antibodies that bind integrin alpha-v beta-8. | |
WO2013186630A3 (en) | Humanized antibodies to ca215 | |
NZ743971A (en) | Antibodies to tau |